DUBLIN, Jan. 13, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that a new presentation related to Dupuytren's contracture (DC) and XIAFLEX ® (collagenase clostridium histolyticum, or ...
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results